Moleculin Biotech, Inc. announced that it has welcomed Dr. Richard Whitley to its Science Advisory Board to guide its development strategy for WP1122 for the potential treatment of COVID-19 and other viral diseases. Dr. Whitley is responsible for the National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group whose role is to perform clinical trials of antiviral therapies directed against medically important viral diseases of children and adults including viruses considered as threats to human health.